1
|
Iwase T, Harano K, Masuda H, Kida K, Espinosa Fernandez JR, Hess KR, Wang Y, Woodward WA, Layman RM, Dirix L, Van Laere SJ, Bertucci F, Ueno NT. Abstract P5-05-04: Myc as a poor prognostic marker for ER+ inflammatory breast cancer (IBC): Quantitative estrogen receptor (ER) expression analysis and gene expression analysis in ER+ IBC vs non-IBC. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-05-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Estrogen receptor-positive (ER+) primary inflammatory breast cancer (IBC) has a poorer prognosis than ER+ primary non-IBC. Our objective was to determine the association between ER positivity and survival outcome in order to elucidate the biological reason that ER+ IBC is more aggressive than non-IBC.
Methods
We retrospectively determined the relationship between ER expression by immunohistochemistry staining and neoadjuvant chemotherapy response as well as survival outcome for 189 patients with ER+ and HER2-negative (HER2-) IBC and 896 case-matched patients with stage III non-IBC seen at MD Anderson Cancer Center between January 1989 and April 2015. We performed gene expression (GE) analysis for 39 patients with ER+/HER2- IBC and 40 patients with non-IBC to detect genes that are specifically overexpressed in IBC. Logistic regression and Cox proportional hazards model were used to determine the predictive and prognostic value of percentages of cells positive for ER and progesterone receptor (PR) among the patients with ER+/HER2- IBC and non-IBC. Recursive partitioning analysis (RPA) was used to determine the optimal cutoff points for ER% and progesterone receptor (PR) % that maximized differences in survival. The identified cutoff points were tested in an external cohort of 192 ER+/HER2- IBC patients from Institut Paoli-Calmettes in France.
Results
The median values for ER% for IBC and non-IBC were 85 (range, 1-100) and 90 (range, 1-100), respectively. The logistic regression model demonstrated a lack of a relationship of ER% with pathological complete response rate to neoadjuvant chemotherapy both in IBC (P=0.29) and non-IBC (P=0.14). Expression of ER was significantly associated with distant disease-free survival (DDFS); hazard ratio (HR), 0.56 [95% CI, 0.37-0.83] per 50% increase in ER%; P<0.05). Also, ER% was significantly associated with overall survival (OS) (HR, 0.40 [95% CI, 0.25-0.63] per 50% increase in ER%; P<0.05). RPA showed that 91.5% and 9.0% were the optimal cutoff points for ER% and PR%, respectively, for DDFS and overall survival in IBC patients. However, the cutoff points could not be validated in the French external cohort. In the GE study, 84 genes were detected as significantly distinguishing ER+ IBC from non-IBC. Among the top 15 canonical pathways shown by IPA, the ERK/MAPK signaling pathway, PDGF pathway, insulin receptor signaling pathway, and IL-7 signaling pathway were associated with the ER signaling pathway. MYC upregulation was observed in three of these four pathways. Indeed, ER+/HER- IBC had significantly higher MYC amplification compared to those with non-IBC (P<0.05) and higher MYC level was associated with poor relapse free survival for IBC (HR, 1.85 [95% CI, 1.05-2.70], P<0.05).
Conclusions
Increased ER positivity was significantly associated with improved survival in ER+/HER- IBC patients. ER+/HER- IBC had several activated pathways with MYC upregulation compared to non-IBC. MYC upregulation was associated with a poor survival outcome for ER+/HER- IBC. The results indicate that MYC is a key gene for understanding the aggressive biological behavior of ER+/HER- IBC.
Citation Format: Iwase T, Harano K, Masuda H, Kida K, Espinosa Fernandez JR, Hess KR, Wang Y, Woodward WA, Layman RM, Dirix L, Van Laere SJ, Bertucci F, Ueno NT. Myc as a poor prognostic marker for ER+ inflammatory breast cancer (IBC): Quantitative estrogen receptor (ER) expression analysis and gene expression analysis in ER+ IBC vs non-IBC [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-05-04.
Collapse
Affiliation(s)
- T Iwase
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| | - K Harano
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| | - H Masuda
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| | - K Kida
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| | - JR Espinosa Fernandez
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| | - KR Hess
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| | - Y Wang
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| | - WA Woodward
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| | - RM Layman
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| | - L Dirix
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| | - SJ Van Laere
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| | - F Bertucci
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| | - NT Ueno
- 1.Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston 2.Section of Translational Breast Cancer Research, The University of Texas, Houston, TX; Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Showa University Hospital, Shinagawa, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Antwerp, Antwerp, Belgium; Institut Paoli-Calmettes, Marseille, France; Oncology Center, Sint-Augustinus Hospital, Antwerp, Belgium
| |
Collapse
|
2
|
Reddy JP, Atkinson RL, Larson RA, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton C, Reuben JM, Krishnamurthy S, Symmans WF, Brewster A, Van Laere SJ. Abstract P4-03-14: Stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-03-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: We hypothesized that normal breast tissue in inflammatory breast cancer (IBC) patients contains intrinsic differences, including increased mammary stem cells and macrophage infiltration, which may promote the IBC phenotype.
Materials and Methods: Normal breast tissue at least 5cm away from primary tumors were obtained from mastectomy specimens. This included an initial cohort of 8 IBC patients and 60 non-IBC patients followed by a validation cohort of 19 IBC patients and 25 non-IBC patients. Samples were immunostained for either CD44+CD49f+CD133/2+ stem cell markers or the CD68 macrophage marker and correlated with IBC status. Automated quantitation of positive cells was employed for the validation cohort. We also examined the association between IBC status and previously published tumorigenic stem cell and IBC tumor signatures in the validation cohort samples.
Results: 8 of 8 IBC normal tissue samples expressed CD44+CD49f+CD133/2+ stem cell markers in the initial cohort as opposed to 0/60 non-IBC normal tissue samples (p=0.001). Similarly, the median number of CD44+CD49f+CD133/2+ cells was 25.7 in the IBC validation cohort as opposed to 14.2 in the non-IBC validation cohort (p=0.007). 7 of 8 IBC samples expressed CD68+ macrophages in initial cohort as opposed to 12/48 non-IBC samples (p=0.001). In the validation cohort the median number of CD68+ cells was 3.7 in the IBC cohort vs 1.0 in the non-IBC cohort (p=0.06). Normal tissue of IBC patients was positively associated with a tumorigenic stem cell signature (p=0.02) and with a 79-gene IBC gene signature (p<0.001).
Conclusions: Normal tissue from IBC patients is enriched for both mammary stem cells and macrophages. Further, normal tissue of IBC patients has higher association with both a tumorigenic stem cell signature and IBC-specific tumor signature. Collectively, these data suggest that normal tissue from IBC patients is distinct from non-IBC normal tissue and may support the hypothesis that a primed normal breast contributes to the development of IBC symptoms upon oncogenic insult. Validation of these results in additional normal tissue in cancer-free women would better determine causality.
Citation Format: Reddy JP, Atkinson RL, Larson RA, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton C, Reuben JM, Krishnamurthy S, Symmans WF, Brewster A, Van Laere SJ. Stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-03-14.
Collapse
Affiliation(s)
- JP Reddy
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| | - RL Atkinson
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| | - RA Larson
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| | - JK Burks
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| | - D Smith
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| | - BG Debeb
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| | - B Ruffell
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| | - C Creighton
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| | - JM Reuben
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| | - S Krishnamurthy
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| | - WF Symmans
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| | - A Brewster
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| | - SJ Van Laere
- MD Anderson Cancer Center, Houston, TX; University of South Florida, Tampa, FL; Baylor College of Medicine, Houston, TX; University of Antwerp, Belgium
| |
Collapse
|
3
|
Peeters DJE, Kumar P, Van der Aa N, Rothé F, Theunis K, Op de Beeck K, Van Laere SJ, Vermeulen PB, van Dam PA, Vincent D, Desmedt C, Sotiriou C, Dirix LY, Ignatiadis M, Voet T. Abstract P1-04-03: Genome-wide analysis of copy number variations and mutation profiles of single circulating tumour cells using massively parallel paired-end sequencing. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-04-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
INTRODUCTION
Recent advances in single cell isolation techniques and next generation sequencing (NGS) have paved the way for the genome-wide molecular analysis of individual circulating tumour cells (CTCs) in patients with metastatic carcinomas. Here we present the results of a pilot study evaluating the feasibility and reliability of NGS of single CTC from whole blood samples.
MATERIALS & METHODS
Single cells of the human breast cancer cell line HCC38 were harvested from spiked blood samples in a semi-automated workflow consisting of immunomagnetic enrichment using the CellSearch system and dielectrophoretic cell sorting using the DEPArray system. DNA was isolated and amplified using the Ampli1 whole genome amplification (WGA) kit and subjected to low-coverage genome-wide paired-end sequencing for copy number variation (CNV) analysis and targeted re-sequencing of 200 cancer-related genes for somatic mutation analysis.
RESULTS
Single-cell WGA products of four HCC38 cells were subjected to whole genome sequencing for CNV analysis. Average coverage depth was 0,68x. At a binning window of 50 kb, detection results of CNVs in single-cell samples were highly consistent (>81% copy number concordance per bin genome wide) with CNV profiles from non-amplified multi-cell samples of the same cell line. We could demonstrate that part of the discordance was due to the acquisition of novel DNA-rearrangements in the single cells. Three of the single-cell WGA products were additionally subjected to targeted re-sequencing for mutation analysis of 200 selected genes, of which the analysis is currently ongoing.
DISCUSSION
Our study demonstrates the feasibility of a comprehensive genome-wide CNV analysis and targeted mutation analysis using NGS of single tumour cells isolated from whole blood samples in a highly automated isolation workflow. This approach provides a robust framework for the study of intercellular heterogeneity within the CTC population in blood samples of patients with (metastatic) breast cancer. In addition, our results document the extent of WGA-induced bias of a recently commercialized PCR-based WGA kit.
These authors contributed equally to the data presented in this abstract.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-04-03.
Collapse
Affiliation(s)
- DJE Peeters
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - P Kumar
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - N Van der Aa
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - F Rothé
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - K Theunis
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - K Op de Beeck
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - SJ Van Laere
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - PB Vermeulen
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - PA van Dam
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - D Vincent
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - C Desmedt
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - C Sotiriou
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - LY Dirix
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - M Ignatiadis
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| | - T Voet
- Translational Cancer Research Unit, Oncology Center, GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp/Antwerp University Hospital, Antwerp, Belgium; Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Single-Cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton-Cambridge, United Kingdom; These authors contributed equally to the data presented in this abstract; Joint Senior Authors
| |
Collapse
|
4
|
Van Laere SJ, Marsan M, Vermeulen PB, Viens P, Barsky SH, Cristofanilli M, Dirix LY, Bertucci F, Robertson FM. Abstract P2-05-04: Comparative expression profiling of patient samples and preclinical models of inflammatory breast cancer reveals gene signatures of epithelial plasticity and suppression of TGFb signaling. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-05-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Genome-wide expression profiling of samples from patients with and without Inflammatory Breast Cancer (IBC) has revealed novel insights into the biology of IBC. The present study was undertaken to compare these novel insights with data obtained from all available preclinical IBC models including 2 new models that we have recently developed that recapitulate the characteristics of IBC including retention of E-cadherin, formation of tumor emboli and encircling lymphoangiogenesis
Materials and Methods: Five replicates of 7 preclinical IBC models (SUM149, SUM190, FC-IBC-01, FC-IBC-02, MDA-IBC-03, KPL-4, and Mary-X) were profiled using Affymetrix HGU133plus2 GeneChips. Using a nearest shrunken centroid algorithm, each expression profile was classified according to an IBC-specific signature identified in patient samples. Available expression profiles were further queried for expression patterns related to Epithelial-to-Mesenchymal Transition (EMT), TGFβ-signaling and IBC-specific patterns of transcription factor activation.
Results: Application of our IBC-specific signature (posterior probabilities exceeded 0.50 in at least 4/5 replicates) revealed that out of 7 pre-clinical models of IBC, 3 of these robustly classified as IBC (FC-IBC-01, FC-IBC-02, and KPL-4). All preclinical IBC models were characterized by retention of E-Cadherin expression, absence of ZEB1 expression, attenuated expression of specific components of the TGFβ pathway (TGFβR2, SMAD3, SMAD7, and TGFβ1), and ambiguous activation patterns of several transcription factors involved in regulating cellular plasticity and cell fate decisions (Up in IBC: NR4A2, RARB/RXRA, PTX3, GSC2, and ZEB1; Down in IBC: SOX10, PAX5, and SMAD2). For each of the molecular alterations described above, Z-scores greater than 2 were achieved in at least 4/5 replicates.
Conclusions: The observations that we have made using IBC patient tumor samples with regards to EMT, cell plasticity and TGFβ-signaling are corroborated in pre-clinical models of IBC using current analytic approaches, despite the fact that expression patterns of the majority of preclinical models of IBC deviate from the IBC-specific expression patterns observed in patient samples. Our data suggest that despite their highly invasive nature, IBC cancer cells retain an epithelial cell phenotype characterized by E-cadherin expression and loss of ZEB1 which appears to be mediated by, amongst others, attenuated TGFβ-signaling. This study strengthens our hypothesis that cancer cells from IBC exhibit cohesive invasion, and invade as a unit, possibly explaining the presence of florid tumour emboli which is a primary characteristic observed in IBC.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-05-04.
Collapse
Affiliation(s)
- SJ Van Laere
- Translational Cancer Research Unit, Wilrijk, Antwerp, Belgium; University of Nevada School of Medicine, Reno, NV; Thomas Jefferson University Hospital, Philadelphia, PA; Institut Paoli-Calmettes, Marseille, Bouches-du-Rhone, France; The University of Texas MD Anderson Cancer, Houston, TX; KU Leuven, Leuven, Belgium
| | - M Marsan
- Translational Cancer Research Unit, Wilrijk, Antwerp, Belgium; University of Nevada School of Medicine, Reno, NV; Thomas Jefferson University Hospital, Philadelphia, PA; Institut Paoli-Calmettes, Marseille, Bouches-du-Rhone, France; The University of Texas MD Anderson Cancer, Houston, TX; KU Leuven, Leuven, Belgium
| | - PB Vermeulen
- Translational Cancer Research Unit, Wilrijk, Antwerp, Belgium; University of Nevada School of Medicine, Reno, NV; Thomas Jefferson University Hospital, Philadelphia, PA; Institut Paoli-Calmettes, Marseille, Bouches-du-Rhone, France; The University of Texas MD Anderson Cancer, Houston, TX; KU Leuven, Leuven, Belgium
| | - P Viens
- Translational Cancer Research Unit, Wilrijk, Antwerp, Belgium; University of Nevada School of Medicine, Reno, NV; Thomas Jefferson University Hospital, Philadelphia, PA; Institut Paoli-Calmettes, Marseille, Bouches-du-Rhone, France; The University of Texas MD Anderson Cancer, Houston, TX; KU Leuven, Leuven, Belgium
| | - SH Barsky
- Translational Cancer Research Unit, Wilrijk, Antwerp, Belgium; University of Nevada School of Medicine, Reno, NV; Thomas Jefferson University Hospital, Philadelphia, PA; Institut Paoli-Calmettes, Marseille, Bouches-du-Rhone, France; The University of Texas MD Anderson Cancer, Houston, TX; KU Leuven, Leuven, Belgium
| | - M Cristofanilli
- Translational Cancer Research Unit, Wilrijk, Antwerp, Belgium; University of Nevada School of Medicine, Reno, NV; Thomas Jefferson University Hospital, Philadelphia, PA; Institut Paoli-Calmettes, Marseille, Bouches-du-Rhone, France; The University of Texas MD Anderson Cancer, Houston, TX; KU Leuven, Leuven, Belgium
| | - LY Dirix
- Translational Cancer Research Unit, Wilrijk, Antwerp, Belgium; University of Nevada School of Medicine, Reno, NV; Thomas Jefferson University Hospital, Philadelphia, PA; Institut Paoli-Calmettes, Marseille, Bouches-du-Rhone, France; The University of Texas MD Anderson Cancer, Houston, TX; KU Leuven, Leuven, Belgium
| | - F Bertucci
- Translational Cancer Research Unit, Wilrijk, Antwerp, Belgium; University of Nevada School of Medicine, Reno, NV; Thomas Jefferson University Hospital, Philadelphia, PA; Institut Paoli-Calmettes, Marseille, Bouches-du-Rhone, France; The University of Texas MD Anderson Cancer, Houston, TX; KU Leuven, Leuven, Belgium
| | - FM Robertson
- Translational Cancer Research Unit, Wilrijk, Antwerp, Belgium; University of Nevada School of Medicine, Reno, NV; Thomas Jefferson University Hospital, Philadelphia, PA; Institut Paoli-Calmettes, Marseille, Bouches-du-Rhone, France; The University of Texas MD Anderson Cancer, Houston, TX; KU Leuven, Leuven, Belgium
| |
Collapse
|
5
|
Peeters DJ, Van den Eynden GG, Rutten A, Onstenk W, Sieuwerts AM, De Laere B, van Dam PA, Peeters M, Pauwels P, Van Laere SJ, Vermeulen PB, Dirix LY. Abstract P2-01-09: Tumor cell emboli in the lung and transcriptional profiles of circulating tumor cells derived from different vascular compartments in patients with metastatic breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-01-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: We have shown that in up to 50% of patients with metastatic breast cancer (MBC) significantly higher numbers of circulating tumor cells (CTCs) can be detected in central venous blood (CVB) as compared to peripheral venous blood (PVB), suggesting that the lungs might retain a substantial number of CTCs from the blood stream (Peeters et al. Br J Cancer 2011). The aim of this study was 1) to investigate the relation between elevated numbers of CTCs and the presence of (intravascular) tumor cell emboli (TCE) in the lung in patients with advanced carcinomas, and 2) to investigate whether CTCs derived from CVB and PVB exhibit differential transcriptional characteristics.
Methods: Seven patients with MBC and 1 patient with metastatic cervical carcinoma, all suffering from end-stage disease, were included in the first part of this study. CTCs were isolated and enumerated with the CellSearch system (Veridex, Raritan, NJ, USA) in 7.5 ml blood obtained from the central venous access catheter (CVB) and/or a peripheral vein (PVB). All blood samples were obtained within 5 days prior to death. The presence of TCE was studied in lung tissue samples obtained at autopsy. For the second study aim, paired CVB and PVB CTC samples were collected from an additional 10 MBC and 2 LABC patients. Transcriptional profiles were obtained for 91 breast cancer related genes as described by Sieuwerts et al. (Clin Cancer Res 2011).
Results: Multiple TCE were observed in 4 out of 6 patients with highly elevated numbers of CTCs (>100 CTC/7.5 ml blood). These TCE were located exclusively intravascularly in 2 patients, while the other 2 patients had a more diffuse infiltration pattern with perivascular and lymphovascular TCE. All 4 patients had a history of rapidly evolving respiratory distress in the last week of life although radiological examination of the lungs did not show significant interval changes. In another 2 MBC patients with >100 CTCs and 2 MBC patients with <5 CTCs, no TCE were observed. Of the 12 patients included for transcriptional CTC analysis, 8 patients had ≥5 CTCs in both blood samples. In line with our previous findings, 5/8 patients had at least a 15% higher CTC count in CVB than in PVB. Unsupervised hierarchical clustering of transcriptional profiles was primarily driven by the absence or presence of CTCs in the blood samples and revealed no significant differences between CTC samples derived from CVB or PVB from the same patient.
Conclusions: TCE were observed in 4 out of 6 patients with highly elevated numbers of CTCs. In these patients, cumulative entrapment of CTCs in the lung might have contributed to respiratory dysfunction. High numbers of CTC might therefore represent an oncological emergency. Transcriptional profiling of 91 breast cancer related genes revealed no substantial difference in gene expression of CTCs derived from CVB and PVB, suggesting that CTC entrapment by the lung is a rather passive process in advanced cancer patients. These findings will be further challenged by comparing the obtained profiles with gene expression profiles of 13 additionally selected homing markers in these samples.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-01-09.
Collapse
Affiliation(s)
- DJ Peeters
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - GG Van den Eynden
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - A Rutten
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - W Onstenk
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - AM Sieuwerts
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - B De Laere
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - PA van Dam
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - M Peeters
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - P Pauwels
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - SJ Van Laere
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - PB Vermeulen
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - LY Dirix
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| |
Collapse
|
6
|
Peeters DJ, van Dam PJ, Wuyts H, Van den Eynden GG, Jeuris K, Prové A, Rutten A, Peeters M, Pauwels P, Van Laere SJ, Hauspy J, van Dam PA, Vermeulen PB, Dirix LY. Abstract P2-01-08: Different numbers and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-01-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The enumeration of circulating tumour cells (CTCs) with the EPCAM-based CellSearch system has prognostic significance in patients with metastatic breast cancer (MBC). However, breast cancer has been shown to be a molecularly heterogeneous disease. The aim of this study was to assess potential differences in the detection and prognostic significance of CTCs according to the immunohistochemically defined molecular subtypes of breast cancer.
Methods: CellSearch CTC counts were obtained from 110 patients with MBC prior to first line systemic treatment, treated at GZA Hospitals Sint-Augustinus between november 2007 and december 2011. Clinicopathological variables were prospectively entered in a database. Based on the St-Gallen surrogate definitions of intrinsic breast cancer subtypes (Goldhirsch et al. Ann Oncol 2011), patients were divided in 5 groups: luminal A (ER/PR+, HER2−, Bloom-Richardson histological grade I-II), luminal B – HER2 negative (ER/PR+, Her2−, grade III), luminal B – HER2 positive (ER/PR+, HER2+, any grade), HER2 positive – non luminal (ER/PR−, HER2+), and triple negative (TN) (ER/PR−, HER2−). Differences in progression free survival (PFS) and overall survival (OS) according to the FDA approved prognostic cut-off of ≥5 CTC/7.5 ml blood were estimated using Kaplan Meier and Cox proportional hazard statistics.
Results: CTC were detected in 78 of 110 (71%) patients. Higher detection rates and numbers of CTC were observed in patients with luminal A and TN breast cancer as compared to patients with luminal B and HER2 positive disease. However, no differences in positivity rates were observed between molecular subtypes according to the 5 CTC prognostic cut-off point (table 1). After a median FU time of 3.1 years, 39 patients had died. In the total study population, the presence of ≥5 CTC was an independent predictor of PFS and OS in multivariate analysis (PFS: HRCTC≥5=2.236 (1.366–3.658), p = 0.001; OS: HRCTC≥5=3.180 (1.553–6.509), p = 0.002). When analyzing subgroups separately, a lower prognostic power was observed in the HER2 positive and luminal B subgroups.
Conclusion: Significant differences were observed in the detection and prognostic significance of EPCAM positive CTC according to the immunohistochemically defined breast cancer subtypes. Interestingly, CTC were detected more frequently in patients with luminal A and TN tumors. Furthermore, our data suggest a lower prognostic significance of CTC evaluation in HER2 positive patients with MBC. Our data independently confirm those reported by Giordano et al. (Ann Oncol 2010) in a large clinically uniform population of patients with MBC before the start of first-line treatment.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-01-08.
Collapse
Affiliation(s)
- DJ Peeters
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - P-J van Dam
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - H Wuyts
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - GG Van den Eynden
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - K Jeuris
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - A Prové
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - A Rutten
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - M Peeters
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - P Pauwels
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - SJ Van Laere
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - J Hauspy
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - PA van Dam
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - PB Vermeulen
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| | - LY Dirix
- GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium
| |
Collapse
|
7
|
Lehman HL, Van Laere SJ, van Golen CM, Vermeulen PB, Dirix LY, van Golen KL. Abstract P3-10-04: Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-10-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
With a 42% and 18% 5- and 10-year respective disease-free survival rate, inflammatory breast cancer (IBC) is arguably the deadliest form of breast cancer. IBC invades the dermal lymphatic vessels of the skin overlying the breast and as a consequence nearly all women have lymph node involvement and ∼1/3 have gross distant metastases at the time of diagnosis. One year after diagnosis ∼90% of patients have detectable metastases, making IBC a paradigm for lymphovascular invasion. Understanding the underlying mechanisms of the IBC metastatic phenotype is essential for new therapies. Work from our laboratory and others show distinct molecular differences between IBC and non-inflammatory breast cancers. Previously we demonstrated that RhoC GTPase is a metastatic switch responsible for the invasive phenotype of IBC. In the current study we integrate observations made in IBC patients with in vitro analysis. We demonstrate that the PI3K/Akt signaling pathway is crucial in IBC invasion. Key molecules involved in cytoskeletal control and cell motility are specifically upregulated in IBC patients compared with stage and cell-type-of-origin matched non-inflammatory breast cancer patients. Distinctively, RhoC GTPase is a substrate for Akt1 and its phosphorylation is absolutely essential for IBC cell invasion. Further our data show that Akt3, not Akt1 has a role in IBC cell survival. Together our data demonstrate a unique and targetable pathway for IBC invasion and survival.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-10-04.
Collapse
Affiliation(s)
- HL Lehman
- The University of Delaware, Newark, DE; Sint Augustine Hospital, Antwerp, Belgium; Catholic University, Leuven, Belgium; Delaware State University, Dover, DE
| | - SJ Van Laere
- The University of Delaware, Newark, DE; Sint Augustine Hospital, Antwerp, Belgium; Catholic University, Leuven, Belgium; Delaware State University, Dover, DE
| | - CM van Golen
- The University of Delaware, Newark, DE; Sint Augustine Hospital, Antwerp, Belgium; Catholic University, Leuven, Belgium; Delaware State University, Dover, DE
| | - PB Vermeulen
- The University of Delaware, Newark, DE; Sint Augustine Hospital, Antwerp, Belgium; Catholic University, Leuven, Belgium; Delaware State University, Dover, DE
| | - LY Dirix
- The University of Delaware, Newark, DE; Sint Augustine Hospital, Antwerp, Belgium; Catholic University, Leuven, Belgium; Delaware State University, Dover, DE
| | - KL van Golen
- The University of Delaware, Newark, DE; Sint Augustine Hospital, Antwerp, Belgium; Catholic University, Leuven, Belgium; Delaware State University, Dover, DE
| |
Collapse
|